Latest Advanced Therapies News

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.